ArticlePharmaceutical biology2021
Anti-inflammatory, expectorant, and antitussive properties of
Article in Pharmaceutical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 14 citations in OpenAlex.
- Inhibitory Effects of Gyeongok-go on Lung Injury in a Chronic Obstructive Pulmonary Disease Mouse Model.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Phytochemicals and Biological Activities of Walnut Septum: A Systematic Review.Antioxidants (Basel, Switzerland) · 2023Review
- Article
- Detoxification technology and mechanism of processing withFrontiers in pharmacology · 2022Article
- Effects of Juhongtanke oral solution on alleviating the symptoms of community-acquired pneumonia: A multicenter, prospective, randomized controlled trial.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
context
objectiveThe anti-inflammatory, expectorant, and antitussive properties of KOG were examined using animal models of respiratory diseases. MATERIALS AND
methodsKOG (100, 200, and 400 mg/kg) was orally administered to ICR mice (
resultsKOG (400 mg/kg) treated mice showed 31.29% and 30.72% (
conclusionsKOG may be a potential therapeutic agent for the treatment of various respiratory diseases, particularly those caused by environmental toxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.